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ABSTRACT
The aim of this study was to establish in vitro analytical methods for assessing an investigated oral BCG vaccine formulation. In addition, in vivo immune response was also evaluated in guinea pigs by determining the potentially protective effect of
the investigated formulation on tuberculosis. The bicinchoninic acid (BCA) method for BCG protein quantitation was developed
for rapid measuring the content of BCG vaccine in the investigated formulation. The analytical method was conducted at 45°C
to offer good precision (coefficient of variation <3.5%) and accuracy (error: -3.6~2.6%) in the range of 150~1000 μg/mL of BCG
vaccine concentrations. In the simulation study of drug release from the investigated formulation in the gastrointestinal tract
under physiological conditions, the investigated oral formulation could protect active component at lower pH (0.1 N HCl) and
completely release active component at higher pH (phosphate buffer, pH 6.8). Although the investigated oral BCG vaccine formulation showed weak immune response to elicit IgG titer, the PPD (purified protein derivative) skin test in guinea pigs by oral
dosing of 4 mg BCG vaccine formulation acquired about equal or higher response than that by 0.5 mg dose by subcutaneous vaccination. The analytical method and in vivo approach could be further applied in the development of oral BCG vaccine formulations.
Key words: oral BCG vaccine, BCA method, intestinal delivery, BCG potency

INTRODUCTION
Tuberculosis (TB) remains one of the major epidemic diseases in many countries. Two million deaths is
estimated due to TB each year world wide (1). In crowded
environment associated with poor ventilation, such as
in public transport vehicles, passengers or travelers are
potentially infected by TB. Human TB has been treated
by chemotherapy for many years. However, the treatment is lengthy and expensive. Therefore, the control
of human TB is still an important public health issue in
developing countries. Prophylactic vaccination may be
a better option for controlling TB. Bacille CalmetteGuerin (BCG), an attenuated strain of Mycobacterium
bovis, was obtained in 1919 after repeated cultures in
bile medium. Various vaccinal substrains, derived
from BCG, have been used since 1920s in an attempt
to prevent human TB(2,3). Recently, in a meta-analysis
of human BCG vaccination trials, BCG was shown to
reduce the risk of pulmonary TB by 50% and the number
of death due to TB by 71% (4). However, the efficacy of
BCG is highly variable and the protection rates of human
* Author for correspondence. Tel: +886-2-87924838;
Fax: +886-2-87924838; E-mail: cch@mail.ndmctsgh.edu.tw

and animal trials range from 0 to 80% (2,5,6). Oral immunization of mice with BCG has been shown to induce
immune response. BCG has a high safe range of dose
following oral administration. The complete form of
Freund’s adjuvant (FCA) is composed of inactivated and
dried mycobacteria to significantly stimulate the cellmediated immunity following the subcutaneous or intraperitoneal injections of FCA. Due to safety consideration, FCA is only used in animal study, but forbidden in
humans. Mice immunized orally or intragastrically with
high doses of BCG showed similar levels of protective
immunity to mice immunized via the subcutaneous route
and induced protection against intravenous challenge
with M. tuberculosis (7). In addition, oral administration of BCG vaccine preparation against TB has several
advantages, including convenient administration, low
cost, and avoidance of needles. A promising oral delivery system might protect BCG vaccine from the damage
by gastric acid, which might provide an effective means
to induce protective systemic immune responses from
the mucosal immunization in gastrointestinal tract (7).
The classical method for measuring the potency
of BCG vaccine involves enumerating colony forming
unit (CFU) in solid medium via cultivation(8). However,
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the approach is cumbersome and time-consuming for
more than 3 weeks. Thus, it is important to establish an
analytical method for fast determination of the content
of BCG vaccine during the development of oral BCG
vaccine formulation. In this study, we attempted to
establish a rapid analytical method to quantitate the
content of BCG vaccine for quality control or formulation evaluation. The protein content of BCG vaccine
in formulations can be determined by BCA (bicinchoninic acid) method (9). Subsequently, the content of BCG
vaccine was calculated using the calibration curve of
pure BCG vaccine. In addition, we intended to develop
an oral BCG vaccine preparation for controlling TB.
The oral vaccine formulation was prepared and evaluated, including in vitro release characteristics in simulated gastrointestinal fluid and the stability of the BCG
vaccine formulation during short-term storage. The
immune response of the oral BCG vaccine formulation
was also investigated in guinea pigs in comparison with
subcutaneous vaccination. The purpose of the study
was to evaluate some important physicochemical properties of the investigated oral BCG vaccine preparation
and to determine the potential immune response related
to TB protection. In addition, BCA method was established and evaluated for determining the content of BCG
vaccine formulation.

MATERIALS AND METHODS
I. Materials
BCG vaccine was provided by Center for Disease
Control, Taiwan. The vaccine has been freeze-dried,
sealed in ampoules and stored at -20°C. The potency of
the BCG vaccine is 3 × 107 CFU/mg. Guinea pigs were
purchased from the National Laboratory Animal Center
(Taipei, Taiwan), and housed at the Laboratory Animal
Research Center, National Defense Medical Center,
with f ree access to food and water. The vivar ium
was maintained on a 12 hr light/12 hr dark cycle, with
room temperature of 22 ± 2°C and relative humidity of
50~70%. All studies were conducted in compliance with
the rules set forth in the ”Guide for the Care and Use of
Laboratory Animals”.
II. Chemicals
BCA reagents were purchased f rom Sigma (St.
Louis, MO, USA), which included BCA solution and
copper (II) sulfate pentahydrate 4% (w/v) solution.
For protein determination, a test reagent was freshly
prepared by mixing 1 part of copper sulfate pentahydrate 4% (w/v) solution with 50 parts of BCA solution.
Phosphate buffered saline (PBS) tablet, bovine serum
albumin (RIA grade), tween 20, goat anti-guinea pig IgG
(whole molecule) peroxidase conjugate and o-phenyl-

enediamine dihydrochloride were also from Sigma (St.
Louis, MO, USA). Hydrogen peroxide and sodium phosphate dibasic were from Wako Chemical (Osaka, Japan).
Sodium dodecyl sulfate (SDS) was from Mallinckrodt
Baker (Paris, France). Citric acid was from Shimakyu’s
Pure (Osaka, Japan). Formaldehyde solution (36~38%)
was ordered from Union Chemical Works Ltd. (Hsinchu,
Taiwan). Other chemicals were of either reagent or pharmacopoeial grade.
III. Methods
(I) Determination of BCG Content by BCA Method
1. Temperature Effect on BCA Method
BCG vaccine aqueous solutions were prepared either
in Milli-Q water alone, or in Milli-Q water combining
with 8% SDS and 0.08 N NaOH, in a range of concentrations from 150 to 1000 μg/mL; the concentrations may
not be equal for different lot samples due to various total
content of BCG vaccine in different vials. Then, a series
of BCG vaccine solutions in two different media were
separately transferred into 10-mL test tubes, 2 mL per
tube. Two sets of test BCG solutions were incubated at
37°C or 45°C for 1 hr. An aliquot of sample, 0.2 mL,
was withdrawn (n = 3) and transferred into a new tube.
Subsequently, 2 mL of BCA reagent was added in and
the mixture was incubated at 37°C for 30 min. Finally,
the concentration of purple complex in each tube was
measured by absorbance at 562 nm using a spectrophotometer (UV-160, Shimadzu Co., Tokyo, Japan).
2. Effect of Incubation Time on BCA Method
Fifteen milliliter of BCG vaccine aqueous solution (1000 μg/mL) was prepared in 8% SDS and 0.08 N
NaOH. And equally divided into three tubes and individually incubated in water bath at 25°C, 45°C, or 60°
C. An aliquot of sample, 0.2 mL was taken (n = 3) at 0,
3, 6, 10, 20, 30, and 45 min, mixed with 2 mL of BCA
reagent and incubated at 37°C for 30 min. Finally, the
absorbance of formed purple complex in each tube was
measured at 562 nm. Milli-Q water (0.2 mL) was used as
blank.
3. Data Analysis
For each tube, the mean absorbance in duplicate
measures was calculated. The calibration curves were
made by plotting the absorbance (after blank correction)
versus the BCG vaccine concentration.
(II) ELISA Method
1. Tests and Controls
Twelve guinea pigs were purchased 1 week prior to
the experiments. Guinea pigs were randomly divided
into 4 groups(A, B, C and D). Group A was used as
control (n = 3) and vaccinated with 0.5 mL normal saline
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subcutaneously. Group B, C, and D, as test groups, were
subcutaneously vaccinated with 0.02 mL, 0.1 mL, or 0.5
mL of BCG vaccine solution (1 mg/mL in normal saline),
respectively. Blood samples were collected from the ear
central artery of the guinea pigs at 3, 4, 5, 6, 7, 8, and 9
weeks after vaccination. Sera were separated from blood
samples immediately by centrifuging at 12,000 rpm for
5 min (FB-4000, Kurabo Industries Ltd., Osaka, Japan)
and preserved at -80°C until assay.
For oral vaccination, 6 guinea pigs were separated
into individual cages and taken off food for 12 hr prior
to oral vaccination. Three guinea pigs, as oral control
(group E), were administered with the oral formulation
containing excipient only. Another three guinea pigs
(group F) were also administered with the oral formulation with a dose of 4 mg BCG vaccine.
2. BCG Preparations
Twenty five milligrams BCG vaccine was suspended
in 1 mL of 10% formaldehyde in PBS (pH 7.4). After
mixing and standing for 30 min, the mixture was centrifuged at 12,000 rpm for 5 min and the supernatant was
discarded. Then, the pellet was washed three times with
Milli-Q water and resuspended in 2.5 mL of PBS, the
final concentration was equivalent to 10 mg/mL BCG
vaccine.
3. ELISA
The ELISA was performed by following the previously reported method (10). Brief ly, polystyrene plates
(EIA/RIA plate, flat bottom treated for enhanced protein
binding, Sigma) were loaded with 100 μL of the BCG
preparations described above in each well. The plates
were then placed in a laminar flow hood until dry. After
washing twice with PBS, each well was blocked with 100
μL of 1% BSA in PBS, pH 7.4. Then, the supernatant
was discarded, each well was filled with 100 μL of test
or control sera (2.5% normal goat sera diluted 1:30 with
0.05% tween 20 in PBS, pH 7.4) and incubated at room
temperature for 90 min. After removing the supernatant,
each well was washed three times with PBS and subsequently incubated for 1 hr at room temperature with goat
anti-guinea pig IgG coupled with horseradish peroxidase (1:1000 dilution). After 1 hr incubation, the plates
were washed with PBS once. Then, 100 μL of freshly
prepared 0.4 mg/mL o-phenylenediamine with 100 μL of
3% hydrogen peroxide was added as enzyme substrate.
The reaction was stopped with 4 N sulfuric acid at 90
min, and the absorbances were read at 492 nm using an
ELISA reader (Anthos 2010, Anthos Labtec Instrument,
Austria)
4. Data Analysis
For each ser um, the mean absorbance value for
duplicate measures was calculated. The means and
standard deviations of the absorbance at 492 nm for the
control and the test groups were obtained. The IgG titer

was expressed as the response ratio using the absorbance
ratio of test to control groups.
(III) Purified Protein Derivative (PPD) Skin Test
At 8 weeks post vaccination, all guinea pigs were
shaved in the region of right-side back and injected intracutaneously with 0.1 mL of the purified protein derivatives (PPD). The skin test reaction of the mean diameter
of the induration was measured after 24 hr (11).
(IV) Oral Vaccine Preparation
Oral BCG preparation was prepared in the lab.
Brief ly, BCG vaccine was mixed with suitable excipients and encapsulated in a specially-designed polymeric
membrane which was prepared following aseptic process
in a cleaning room under 20°C. The oral deliver y
system was designed to resist the attack of gastric fluid,
and to release the active component of BCG vaccine at
neutral pH in intestinal tract. The delivery system was
also prepared to carry fluorescein sodium as a releasing
marker to substitute for BCG vaccine in assessing the
release characteristics.
(V) Release Studies
The investigated oral delivery system, containing
1 mg of fluorescein sodium with the same excipients as
oral BCG vaccine formulation, was used to investigate
the release characteristics. USP disintegration apparatus with disc was also employed. For initial 2 hr, 1
L of 0.1 N HCl was used as the test medium and run at
37°C. Following, the test medium was switched to the
phosphate buffer (pH 6.8) and run for another hour. At
suitable time intervals, an aliquot of sample, 0.5 mL
was withdrawn from the medium and diluted 200 times
with alkaline borate buffer (pH 9.0). After mixing, the
f luorescent intensitity of mixtures was measured using
a f luorophotometer (RF-5301PC, Shimadzu Co., Kyoto,
Japan) at 485 nm excitation and 515 nm emission.
(VI) Stability of Oral BCG Vaccine Formulation
The oral BCG vaccine formulation was stored at 5°C
and -20°C to investigate the stability of BCG vaccine
during short-term storage. At 0, 1 week, 1 and 2 month
(two additional points, 2 and 3 week for 5°C), samples of
the oral BCG vaccine formulation were withdrawn. The
potency of BCG vaccine in the formulation was determined by cultivating the BCG vaccine in LowensteinJensen medium after suitable dilution (20~60 CFU/0.1
mL in PBS) according to the WHO viability method (8).
The remained BCG potencies at different sampling times
in oral vaccine formulation were calculated taking the
CFU values of original BCG vaccine as 100%.
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RESULTS

thereafter in simulated intestinal fluid for another 1 hr as
shown in Figure 3. For initial 2 hr, the marker (fluorescein
sodium) was undetected, but it was completely released in

I. BCG Content Determined by BCA Method
The protein concentration in BCG vaccine solution
was determined by BCA method. Proteins reduce Cu 2+
to Cu+ to form a purple complex with BCA and display
an absorbance maximum at 562 nm. The calibration
curves of BCG vaccine is illustrated in Figure 1 by plotting the net absorbance (after deducting the blank absorbance) versus BCG concentration. The linear equations
of calibration curves for determining BCG concentrations by BCA method at 37°C and 45°C with or without
8% SDS and 0.08 N NaOH were shown in Table 1. These
results indicated that the BCA method at higher temperature (45°C) with SDS and NaOH presented better precision and accuracy (C.V. < 2.0% and error: -0.53~0.22%)
for measuring BCG vaccine. The time course of the
resultant absorbances in three different temperatures
for BCG vaccine determination is shown in Figure 2.
After 30 min, the absorbances of three temperatures
were about equal, but incubation at 60°C associated with
higher reaction rate displayed higher absorbances for
initial 20 min as compared with 25°C and 45°C.

Table 1. Linear equations, precision and accuracy for using BCA
method to determine BCG concentration in various conditions
C.V.
(%)

Error (%)

37°C, (–)a

y = 0.000124x + 0.0589,
R2 = 0.9975

2.5

-2.40~1.39

37°C, (+)b

y = 0.000171x + 0.0712,
R2 = 0.9968

3.0

-3.62~2.51

45°C, (–)

y = 0.000158x + 0.0608,
R2 = 0.9944

3.5

-1.89~2.64

45°C, (+)

y = 0.000217x + 0.0693,
R2 = 0.9998

2.0

-0.53~0.22

108

(A)

0.25

Relative absorbance(%)

The release profiles of investigated delivery system
were determined in simulated gastric f luid for 2 hr,

Absorbance

Equation

The analytical BCG vaccine concentration ranged from 150 to 1000
μg/mL.
a
BCG vaccine in the aqueous solution without 8% SDS and 0.08 N
NaOH.
b
BCG vaccine in the aqueous solution with 8% SDS and 0.08 N
NaOH.

II. Release Characteristics
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Figure 2. The effect of reacting temperature on the analysis of BCG
vaccine determined by BCA method.
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Figure 1. Calibration curves of BCG vaccine determined by BCA
method at 37°C (A) and 45°C (B).
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Figure 3. The release profile of the established oral delivery system
in simulated physiological pH media by using sodium fluorescein as
an active component.
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20 min at the medium of pH 6.8. In vitro release results
indicated that the designed delivery system could provide
an intestinal delivery to completely protect BCG vaccine
from the attack of gastric fluid during the transit through
stomach and release BCG exactly in intestinal tract.
III. Stability of BCG in Oral Delivery System
The change of potencies of BCG vaccine by enumerating the CFU value is shown in Figure 4 in investigated
oral formulation during the storage of 8 weeks. The oral
BCG vaccine formulation was stored at -20°C or 5°C and
the potencies of BCG vaccine fell to the level of 10~20%.
A higher potency of BCG vaccine is maintained under
lower temperature. Our results were similar to the report
of Aldwell et al.(12). They prepared BCG vaccine in a
lipid-based formulation. Formulated BCG vaccine could
be stored for 8 weeks to maintain suitable potency at
temperatures lower than 5°C.
IV. IgG Titer
The ELISA result is shown in Figure 5 for measuring the IgG titer in guinea pigs following subcutaneous

120

V. Tuberculin Skin Testing
To determine the dose response of BCG vaccine
following subcutaneous vaccination in guinea pigs, we
also measured the mean diameter of the induration after
intradermal injection of tuberculin (PPD) at 8th week
after vaccination. These results were compared with the
investigated oral BCG vaccine formulation (Table 2). In
two control groups, either subcutaneous or oral administrations did not elicit significant response to tuberculin.
But the tuberculin test response for various doses of
BCG vaccine in subcutaneous injection showed a linear
relationship of the mean diameter and the logarithm of
dosing volume (Figure 6). In addition, the oral vaccination group demonstrated a promising effect similar to the
subcutaneous injection of 0.5 mg BCG vaccine.

5ºC
16

-20ºC

80
60

12

40
20
0

0

10

20

30

40

50

60

70

Diameter (mm)

BCG potency (%)

100

injection with various doses of BCG vaccine. The IgG
immune response followed biphasic change during 8
weeks of post-vaccination period. Two peaks appeared
at 4th and 7th weeks with a trough at 5th week. The
IgG response was enhanced as the dose of BCG vaccine
increased. These results also indicated that oral vaccination only elicited weak IgG response (Figure 5). The
immune responses in IgG titers including control (normal
saline injection), oral BCG formulation and excipient
(oral delivery) groups were very weak.

4

Time (day)

Figure 4. The degradation of BCG vaccine during storage at 5°C
and -20°C.

-1.5

-1

-0.5

0

Figure 6. Dose dependent immune response of tuberculin skin test
by subcutaneous (SC) injection of BCG vaccine.

8.00

Response ratio

0
-2

log Dose (mg)

10.00

SC inj 0.02 mg BCG vaccine
SC inj 0.1 mg BCG vaccine
SC inj 0.5 mg BCG vaccine
Oral 4 mg BCG vaccine

6.00

Table 2. Results of the tuberculin skin test
Group

Delivery
route

BCG dose
(mg)

Diameter (mm)
Mean ± S.D.

A (control)

SC inj

0

0

B

SC inj

0.02

6.7 ± 3.1

C

SC inj

0.1

8.3 ± 4.2

D

SC inj

0.5

10.7 ± 0.6

E (control)

Oral

0

0

F

Oral

4

12.0 ± 2.0

4.00
2.00
0.00

8

2

4

6

8

10

Time (week)

Figure 5. The humoral IgG immune response of BCG vaccine
following subcutaneous (SC) injection or oral administration.
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DISCUSSION
In this study, we intended to develop an oral BCG
vaccine formulation. From the preliminary animal studies, the developed oral BCG vaccine preparation seemed
to elicit immune response from oral vaccination. The
investigated BCG vaccine formulation might be further
optimized to fabricate an oral BCG vaccine preparation. BCG is a live attenuated vaccine and the acquired
resistance against tuberculosis depends on the survival,
multiplication and persistence of BCG in the host organs.
The viability and stabilization of BCG vaccine in a
delivery system are important factors to achieve good
immunogenicity(13). Because live or dead BCA vaccines
can not be differentiated in BCA method, the short-term
viability preservation was also investigated by traditional
solid medium cultivation method in the study. In addition, BCA method was established to measure the protein
content and determine the concentration of BCG vaccine.
BCA method could be employed to quickly determine the
content of BCG vaccine as long as the oral BCG vaccine
preparation did not contain protein, copper or other
interfering components. Content uniformity is also an
essential requirement for low dose preparations. Since
the investigated oral formulation only contained few
milligrams of BCG vaccine, it is necessary to analyze its
content uniformity. Viability and content uniformity are
two important items to optimize the oral BCG formulation. In this study, BCG vaccine incubated with 8% SDS
and 0.08 N NaOH has higher absorbance (Figure 1) in
BCA method. It could be the lipophilic cell wall of BCG
vaccine to be efficiently disrupted by surfactant SDS in
alkaline condition to achieve better protein recovery.
Many analytical methods have been reported for
measuring BCG vaccine potency. The tetrazolium salt,
3-(4,5-dimethy thiazol-2-yl)-2,5-diphenyltetrazolium
b r om id e ( M T T ) a nd 2 , 3 - bi s - (2-me t hox y- 4 -n it r o sulphonyl)-(2H)-tetrazolium-5-carboxanilide (XTT), are
used as alternative substrates in the assay of BCG (14).
The method may achieve reproducible results, but the
assay needs incubation of at least 2 days, which is not
suitable for the investigation of oral BCG vaccine formulation. In addition, Kuan and Lin reported a method
using capillary electrophoresis to analyze and detect
the PCR products of BCG vaccine genomic DNA. The
method offers advantages of short running time and reliable identification (15), however, the analysis might be
devoid of quantitative determination of BCG vaccine.
Estimation of adenosine triphosphate (ATP) using
the firef ly bioluminescence reaction was also applied
to quantitate living bacteria in BCG vaccine (16). The
bioluminescence method is sensitive and time saving.
However, the ATP assay method has a potential variation of more than 20% due to significant ATP degradation during the extraction process. The bioluminescence
method might be combined with the established BCA

method for rapid assessment of the potency of investigated BCG formulation.
In the study, f luorescein sodium was used as a
marker to study the release characteristics of investigated oral formulation. The approach provided a simple,
safe and fast determination for assessing the oral delivery system. Fluorescein sodium with strong fluorescent
intensity is easily measured by fluorometry. In addition,
the small molecule is safe and thus avoiding any possible
contamination or infection due to BCG vaccine.
T he shor t-t e r m st abi l it y st udy i nd icat e d t h at
BCG vaccine is a heat liable microgranism. At higher
temperature, the BCG vaccine lost potency quickly. The
viability of BCG vaccine only maintained for few hours
at 37°C after opening. It might explain the large variation of protection rates in BCG vaccination when BCG
vaccine is not appropriately stored or it is exposed long
time to hot weather by vaccinators.
Many studies assessed the immune response of BCG
vaccine by measuring IgG titer which is also used in the
diagnosis of tuberculosis (11, 17). In this study, ELISA
was employed to determine the specific BCG vaccine
antibody using the formaldehyde-treated BCG vaccine as
a primary antigen. Although the determined IgG titers
were low, the immune response was proportional to the
dose of BCG vaccine in subcutaneous vaccination (Figure
5). However, the IgG titer in oral vaccination was poor
and similar to the control group. The result indicated
that the BCG vaccine of oral formulation through mucosal immunosystem only elicit a lower immune response
in IgG. It is consistent with the mucosal immunosystem
to secrete predominantly IgA(18). For PPD skin test, we
found that the mean diameters of induction in subcutaneous vaccination increased as the vaccinated dose
increased. Guinea pigs by oral dosing 4 mg of BCG
vaccine formulation acquired about equal or slightly
higher response than that by 0.5 mg dose in subcutaneous vaccination. The response in PPD skin test have
been reported to correlate with IFN-γ assay and lymphocyte proliferation assay which are used to evaluate the
cell-mediated immune response of BCG vaccine (19). In
addition, the mycobacteria of BCG, as facultative intracellular parasites, can survive within macrophage to
initiate a specific T cell-mediated immune response for
providing protective immunity.
Overall, we developed an oral BCG vaccine formulation to protect the viability of BCG vaccine for eliciting immune response in gut-associated lymphoid tissue
in oral vaccination. The oral formulation could maintain
live bacilli in short-term storage below 5°C. In addition, we established an analytical method for measuring
BCG vaccine content by BCA method, which provided a
simple and rapid approach for further determination of
the content uniformity in the development of BCG vaccinal formulation.
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